

Young people with type 1 diabetes: attitudes, perceptions and experiences of diabetes management and continuous subcutaneous insulin infusion therapy

RUNNING TITLE:

Young people with type 1 diabetes

AUTHORS:

Lin PERRY^{PhD, MSc, RN}

Faculty of Health

University of Technology Sydney

South Eastern Sydney Local Health District

Prince of Wales Hospital, Randwick

New South Wales, 2031, Australia

Lin.Perry@uts.edu.au

Steven JAMES^{PhD Candidate, RN, CDE}

Faculty of Health

University of Technology Sydney

Broadway, Ultimo

New South Wales, 2007, Australia

+1 705 789 2311, ext. 2312

Stevenjames_76@yahoo.co.uk

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1111/jep.12670](https://doi.org/10.1111/jep.12670)

Katharine STEINBECK ^{MBBS, FRACP, PhD}

Sydney Medical School

University of Sydney/

Academic Department of Adolescent Medicine

The Children's Hospital at Westmead

New South Wales, 2145, Australia

Kate.Steinbeck@health.nsw.gov.au

Janet DUNBABIN ^{PhD, BAgSc}

Faculty of Health and Medicine

University of Newcastle

University Drive, Callaghan

New South Wales, 2308, Australia

Janet.Dunbabin@newcastle.edu.au

Julia LOWE ^{MBChB, FRCP, MMedSci}

Department of Medicine

University of Toronto/

Division of Endocrinology and Metabolism

Sunnybrook Health Sciences Centre

Bayview Avenue, Toronto

Ontario, M4N 3M5, Canada

Julia.Lowe@sunnybrook.ca

CORRESPONDING AUTHOR:

Steven JAMES

Faculty of Health

University of Technology Sydney

15 Broadway

Ultimo, New South Wales, 2007, Australia

+ 1 705 789 2311, ext. 2312

Stevenjames_76@yahoo.co.uk

KEYWORDS:

Attitude; Experiences; Health Transition; **Continuous Subcutaneous Insulin Infusion Systems; Paediatric**; Type 1 Diabetes Mellitus; Young People.

FUNDING:

This work was supported by **a grant from the** New South Wales Institute for Rural Clinical Services and Teaching (now Health Education and Training Institute Rural Portfolio, New South Wales Health).

CONFLICTS OF INTEREST:

None.

Author Manuscript

ABSTRACT:

Rationale, aims and objectives

Continuous subcutaneous insulin infusion (CSII; insulin pump) use is increasing. However, there is little information about how this technology is used compared to other insulin delivery methods (i.e. injections) by young people with type 1 diabetes in Australia. This study explored young people's attitudes, perceptions and experiences with diabetes management comparing those using and not using CSII, and proportions likely to transition to adult services requiring initiation and/or support for CSII use.

Methods

A survey was undertaken of young people (aged 12 - 18 years) with type 1 diabetes and their parents/guardians living in Hunter New England, Australia, using a questionnaire designed to collect quantitative, descriptive and demographic data. Most questions were based on previously developed and validated instruments. In total 107 respondents returned partially or fully completed questionnaires.

Results

Respondents had positive attitudes and perceptions of their self-efficacy and diabetes management, but were moderately disturbed by their diabetes and reported experiencing sub-optimal management outcomes. Patterns of associations were demonstrated between knowledge, attitudes and experiences of diabetes modelled by regression analysis. There were no statistically significant differences in responses between users and non-users of CSII. Over 40% indicated their intention to use the technology as adults.

Conclusions

Opportunities for enhanced diabetes service support were clear, and CSII did not appear to be used to its full potential. Service redesign could enhance support for this young population using all preferred insulin delivery methods, and should align to patients' goals and preferences to maximise service and patient gain.

Author Manuscript

INTRODUCTION:

More than two decades ago the landmark Diabetes Control and Complications Trial¹ established that the onset and progression of micro-vascular complications in type 1 diabetes (T1D) can be significantly reduced by tight glycaemic control. As a method of insulin delivery continuous subcutaneous insulin infusion (CSII; insulin pump) therapy offers potential towards achieving this. Clinical and quality of life improvements have been demonstrated for some children and adults²⁻¹²; however, living with CSII is not without challenges. Device malfunction and infusion set/site failures are not uncommon and may increase hypoglycaemia or ketoacidosis risk; CSII use has been reported to increase Emergency Department (ED) presentation rates¹³⁻¹⁵.

Australian data indicate a consistent increase in rates of CSII commencement¹⁶. By 2011 around 10% of this T1D population were using this technology¹⁶, broadly similar to data from Sweden, the Netherlands and Germany¹⁷, though lower than that reported in the United States^{18, 19}. A high proportion of CSII users in Australia are young people; one third of people with type 1 diabetes in Australia aged under 20 years use CSII technology. 40% of all new users between 2008 - 2010 were under 18 years of age¹⁶. This represents a large number considering more than half of all new cases of type 1 diabetes occur in people aged under 18 years, with rates three times as high among 0 - 14 year olds (24 per 100,000 population)²⁰.

Australian CSII uptake may have been influenced by the introduction of a government subsidy for low income families with children with T1D in 2008²¹. The sum of Au\$6,400 (or

80% of the device cost) may be available to persons with type 1 diabetes aged under 18 years that have an annual family income under Au\$73,146 or receive government income support payments; varying support with the 20% co-payment is available for those that qualify for the maximum device subsidy. Besides personal finance, CSII devices in Australia may also be obtained through private health insurance, clinical trial enrolment, or through charitable donations. The majority (89%) of CSII users receive financial assistance to acquire their device, with almost all of these (97%) using private health insurance¹⁶. The consequence of this method of purchase is that usage is more commonplace in higher socio-economic areas (14% versus 6%)¹⁶. Regardless of age, the consumables needed for patients with type 1 diabetes to use CSII technology are subsidised by the Australian Government, subject to eligibility criteria²².

Despite increasing CSII use, there is little Australian information about the everyday experiences of young people with T1D, or their intentions towards CSII use once they become adults. The aim of this study was to explore young people's attitudes, perceptions and experiences with diabetes management, comparing those using and not using CSII (i.e. delivering insulin via injections); and to estimate the proportion likely to transition to adult services requiring initiation and/or support for CSII use.

METHODS:

This was a cross-sectional survey conducted in collaboration with Hunter New England Local Health District (HNELHD), the public healthcare provider for around 850,000 residents

across 130,000 square kilometres of metropolitan, regional and rural New South Wales (NSW), Australia²³. Approval was obtained from Hunter New England (HNE) Health and University of Newcastle Human Research Ethics Committees.

Young people aged 12 - 18 years with T1D and their parents/guardians residing within the HNE region, were identified through a HNELHD clinical database in 2011. All had access to specialist diabetes care either through attendance at a specialist multi-disciplinary diabetes service located at a tertiary metropolitan children's hospital, or through their regular specialist paediatric outreach program. Initial contact came from recipients' diabetes nurse educators. Packages of introductory letters, information statements, consent forms and the questionnaire were posted to the address recorded in case records. Recipients were asked to return a signed consent form and completed questionnaire in the included stamped, addressed envelope. In the event of no response one reminder package was posted.

The questionnaire was constructed by research team members and reviewed by local diabetes clinicians. Most questions were derived from or based on previously developed and validated instruments. The questionnaire contained the Perceived Diabetes Self-Management Scale (PDSMS), an eight-item uni-dimensional measure of self-perceived diabetes self-management efficacy scored as a five-point Likert-type scale (1 = Strongly disagree, 5 = Strongly agree). This measure has previously demonstrated construct, discriminant and predictive validity²⁴, and in this study a Cronbach alpha of .92 indicated internal consistency.

Perceptions of disease knowledge, self-care independence and sense of disturbance (upset or annoyance) caused by diabetes were measured using four questions developed by Viklund et al²⁵. Responses were via visual analogue scales ranging from 0 - 100 mm with five anchor points; higher scores indicated greater knowledge, independence and disturbance, scaling from 'Nothing' to 'Everything' (knowledge) and from 'Never' to 'All the time' (other items).

Demographic data were sought, and residential area was categorised according to the Australian Standard Geographical Classification²⁶. Questions sought diabetes-related clinical data to augment identification of young people's experiences, including self-report of HbA1c values, hypoglycaemic episodes, diabetes-related ED presentations and hospital admissions, and the occurrence of ophthalmic examination and urine checks for renal disease within the past year. Three closed questions enquired about episodes of CSII dysfunction or discontinuation, and two questions sought to estimate the proportion of paediatric patients transitioning to adult services in the next five years likely to require CSII initiation, on-going support and monitoring.

Quantitative data were entered into SPSS Version 22 software for analysis and all test and model assumptions were checked and met. Comparisons were drawn between CSII users versus non-users using appropriate analyses. Four PDSMS items²⁴ were reverse-coded prior to summation of the eight-item measure. Data for the PDSMS items, perceptions of disease knowledge, self-care independence and sense of disturbance caused by diabetes²⁵, episodes of hypoglycaemia and service usage were analysed using the Mann-Whitney *U*-test; most recent

reported HbA1c values were analysed using Student's *t*-test. Categorical data on self-reported hypoglycaemia, ophthalmic and urine checks, service usage and estimation of proportions of patients likely to transition to adult services requiring CSII initiation and/or support were analysed using the Chi-square or Fisher's Exact test. **Analyses pertaining to ophthalmic and urine checks were undertaken on data from all respondents, then, in light of complication screening recommendations for young people, solely for those with greater than five years type 1 diabetes duration²⁷.**

Multiple regression analyses were used to identify predictors of young people's attitudes, perceptions and experiences with diabetes management, with dependent variables of the summary scores for the PDSMS, perceived diabetes-related knowledge, independence in changing insulin doses, independence in care of diabetes overall, disturbance caused by diabetes and most recent reported HbA1c values. **In light of the well-known associations between attitudes, beliefs and behaviours²⁸, each** was also examined as potentially predictive variables. **Other potentially predictive variables were selected based upon clinical insights and prior studies:** current CSII use (Yes/No), sex, age, diabetes duration and metropolitan versus non-metropolitan residence^{7, 29, 30}. Data were entered into each model using the backwards method, with missing data deleted listwise. A p value of < .1 was applied for exclusion from the model and < .05 was taken to indicate significance.

RESULTS:

Of the 295 questionnaires distributed 107 (36.3%) were returned partially or fully completed; response rate was difficult to determine as the recorded address may not have been current and not all potential participants may have received the survey. Where reported, 49 questionnaires were completed by a young person alone, four by parents alone and 53 by a young person and parent together. The young people were mean age 15.1 years. The sexes were approximately equally represented with 57.9% male; 5.6% self-identified as Aboriginal and/or Torres Strait Islander. Respondents reported mean age at type 1 diabetes diagnosis and diabetes duration of 9.3 and 5.9 years, respectively. Almost one third (30.8%) resided in metropolitan areas; almost all (91.6%) were full-time students and lived with family members (95.3%) (Table 1). CSII was the current method of insulin delivery for 42 (39.3%) respondents, with a further eight having used this in the past (n = 50, 46.7%); mean (SD) age at commencement was 12.4 (2.6) years. Where reported, current CSII users and non-users differed in that current users were significantly younger at diagnosis, with significantly longer diabetes duration (Table 1).

Attitudes and perceptions

Respondents' (n = 86) attitudes towards and perceptions of their diabetes management self-efficacy were largely positive. They mostly agreed that they handled themselves well with regards to their diabetes; were able to manage things related to their diabetes as well as most others; that they succeeded in the things they did to manage their diabetes; and were able to achieve management plans (Table 2). Mostly, they did not find it difficult to find effective solutions for management problems; efforts to change things about their diabetes worked;

typical plans for diabetes management worked out well; and management turned out as planned. Reported attitudes and perceptions were not statistically significantly different between current CSII users and non-users for individual items or the measure summaries (Table 2). Respondents were significantly more likely to report greater self-efficacy for diabetes self-management (have a higher PDSMS summary score) if they were younger, reported greater independence in their diabetes care, were less disturbed by their diabetes diagnosis, and reported lower most recent HbA1c values (Table 3).

Overall, 87 respondent **perceived their** diabetes-related knowledge as moderate (median (25, 75 quartile) score 75 (63, 76) of 100). Respondents reported changing their insulin dosages independently some of the time (scoring 69 (21, 94) of 100) and that they were somewhat independent in overall diabetes management (scoring 76 (62, 98) of 100). Again, there were no statistically significant differences in responses of current CSII users ($n = 36$) and non-users ($n = 51$) for these three items. Respondents were more likely to report independence in changing insulin dosages if they reported greater management self-efficacy (a higher PDSMS score), greater independence in their diabetes care overall, and had a higher most recent HbA1c (Table 3). They were more likely to report independence in their diabetes care overall if they were older, reported greater management self-efficacy (a higher PDSMS score), greater diabetes-related knowledge and independence changing insulin dosages (Table 3).

Experiences

Respondents' (n = 86) indicated they were disturbed by their diabetes for about half the time (median (25, 75 quartile) score of 50 (25, 75)), with no significant difference between CSII users and non-users. Respondents were more likely to report disturbance by their diabetes if they resided in non-metropolitan locations, perceived less self-efficacy to self-manage their diabetes (a lower PDSMS score), and reported greater diabetes-related knowledge (Table 3).

Patterns of associations between knowledge, attitudes and experiences of diabetes modelled by regression analysis are illustrated in Figure 1.

Recent HbA1c values were supplied by 65 (60.7%) respondents; mean (SD, min, max) values were 8.0% (1.6%, 5.2%, 12.9%) (Table 1). Recent values were considered (n = 80) higher than usual by 25 (31.3%), usual for 33 (41.3%) and lower than usual by 10 (12.5%). Whilst there was no statistically significant difference between values reported by current CSII users and non-users (n = 28, mean (SD, min, max) 8.3% (1.4, 6.3, 11.2) versus n = 37, 7.8% (1.7, 5.2, 12.9); $t = 1.454$, $P = .151$ (95% CI = -.21, 1.36)), a mean difference of 0.5% might be considered clinically significant. Values were non-significantly higher in respondents who resided in a non-metropolitan location (n = 39, 8.2% (1.7, 6.0, 12.9) versus n = 26, 7.7% (1.4, 5.2, 10.8); $t = -1.279$, $P = .206$ (95% CI = -1.31, .29)).

In the previous month hypoglycaemia was reported by 73 (77.7%) of 94 respondents, who reported experiencing a median (25, 75 quartile) 3 (1, 5) hypoglycaemic episodes per week. There was no statistically significant difference in responses from current CSII users compared to non-users for both any occurrence (yes/no) (n = 28 (75.7) versus n = 45

(78.9%); $X^2 = 0.138$, $P = .71$) and frequency (2.5 (1.25, 4) versus 3 (1, 5) events). Of 87 respondents, 33 (37.9%) reported having a hypoglycaemic episode that required assistance since their diabetes diagnosis; not statistically significant, these severe episodes were reported by a greater proportion of non-CSII users than CSII users ($n = 23$, 45.1% versus $n = 10$, 27.8%). The method of insulin delivery utilised during these episodes was, however, unknown.

When asked about diabetes complications screening within routine care in the previous year, 58 of 87 respondents (66.7%) reported having an ophthalmic examination for retinal disease and 66 (75.9%) reported urine checks for renal disease. Distribution was similar for CSII users and non-users: ophthalmic examinations ($n = 25$ (69.4%) versus $n = 33$ (64.7%); $X^2 = .213$, $P = .644$); urine checks ($n = 27$ (75%) versus $n = 39$ (76.5%); $X^2 = .025$, $P = .875$). Of respondents with greater than five years diabetes duration ($n = 46$), 34 (73.9%) reported having an ophthalmic examination and 37 (80.4%) reported having a check for renal disease. However distribution was not always similar for CSII users and non-users: for ophthalmic examinations ($n = 19$ (73.1%) versus $n = 15$ (75%); $X^2 = .022$, $P = .883$) and urine checks ($n = 18$ (69.2%) versus 19 (95%); Fisher's exact = No value, $P = .057$), respectively.

Diabetes-related care was commonly accessed through acute services. Within the previous year, 11 of 92 respondents (12%) reported a diabetes-related ED presentation, and 27 of 96 respondents (28.1%) reported a diabetes-related hospital admission (excluding an admission for T1D diagnosis); overall, 33 respondents (30.83%) had used acute services for diabetes-

related problems (excluding for T1D diagnosis). Again there was no statistically significant difference in responses of CSII users compared to non-users (Table 4).

Future preferences

Substantial numbers ($n = 39$, 41.1%) of the 95 respondents who indicated their future preferences for insulin delivery method intended to use CSII as an adult; this included 31 of 42 (73.8%) current CSII users and 8 (15.1%) of 53 (of 65) respondents not presently using this technology. Although not statistically significant, a greater proportion of those intending to use CSII lived in non-metropolitan settings ($n = 25$ (64.1%) versus $n = 14$ (35.9%)).

Additionally, 41 respondents either had not thought about it or could not anticipate their future plans, with 10 (23.8%) current CSII users planning to discontinue this method of insulin delivery.

DISCUSSION:

The majority of children and adolescents with T1D had positive attitudes and perceptions of their self-efficacy and diabetes management, but were moderately disturbed by their diabetes and experienced sub-optimal management outcomes. Overall there was no statistically significant difference in responses from CSII users and non-users. A large proportion of respondents indicated that they intended to use this therapy when accessing adult diabetes services; information of value for health service planning.

Findings indicate the inter-related roles of perceived self-efficacy, diabetes-related knowledge, independence in diabetes management and sense of disturbance caused by diabetes (Figure 1). However the influence of age appeared complex. Perhaps younger respondents perceived they had better diabetes self-efficacy and knowledge because they were shielded by their parents' contribution to their management; consistent with increasing independence in diabetes care overall with increasing age. With greater diabetes knowledge linked with greater sense of disturbance by their diabetes, education needs to be tailored to achieve better self-management, as it may otherwise function to cause anxiety or distress and may result in worse outcomes. The suggestion of greater disturbance in non-metropolitan residents was perhaps linked to the greater isolation and lack of peer support experienced in rural areas³¹ and warrants further exploration.

Overall, the patterns of glycaemic control reported by these participants could not be described as optimal³²⁻³⁴. Findings were consistent with previous studies of young adults with T1D in this region of NSW^{35, 36} and elsewhere³⁷⁻³⁹, and are cause for concern, especially considering the accompanying positive attitudes, high perceived self-efficacy and diabetes self-management abilities also reported. High rates of hypoglycaemia and acute service usage for diabetes-related problems were also consistent with findings from young adults with T1D^{35, 13, 36}. CSII use did not appear to confer a significant advantage in glycaemic control, although this study lacked statistical power to demonstrate this. However findings highlight the importance of good preparation and support for CSII use.

There is broad consensus that a prospective CSII user should be assessed by a multidisciplinary team in relation to multiple criteria to ensure appropriate targeting of this technology^{16, 40}. In this study it is unclear whether and how this, and re-evaluation post commencement, occurred. Respondents' CSII use (39.3%) was broadly consistent with national data, supporting the generalisability of findings in this young population; one third of people with type 1 diabetes aged under 20 years across Australia are reported to use CSII technology¹⁶. Eight current non-users had used CSII in the past. Varied rates of discontinuance have been reported, and although up to 18% of children and young people have been reported to discontinue CSII within the first few years of use^{10, 29}, lower rates have also been reported^{41, 42}. Given the cost to provide CSII and the human resources required to support CSII users, discontinuance and any failure to improve real life clinical outcomes are disappointing⁴³. One reason for sub-optimal outcomes might be that stretched diabetes teams, especially in rural areas, lack adequate specialist resources to provide the more complex and time consuming support needed to optimise results^{35, 44}. Where this is the case, service redesign is required to improve support particularly but not exclusively for CSII users. Other technologies such as video-conferencing may also be of benefit⁴⁵, and should be explored.

Limitations of the study include the use of self-report data, and sampling from only one regional health service. The sample size was relatively small and the survey entailed only brief assessments of perceived disease knowledge, self-care independence and sense of disturbance caused by diabetes. No data were available on participants' and their parents'/guardians' economic status, and we were therefore not able to consider whether

financial concerns such as lack of access to private insurance or loss of the Australian Government subsidy for a CSII device at age 18 years may have, for example, influenced access or intention to use CSII²¹. The survey was completed, variously, by the young person, their parents, or both; findings therefore contain a mix of the young person's independent views and what the parents think their views are. We set out to obtain the views of young people, and accepted that some parental input might be needed to obtain this, even to the extent of a parent responding as proxy. The strengths of the study derive from successfully recruiting a 'hard to access' group across a wide and diverse geographical and sociological area, the majority of whom completed the survey unaided. Incremental changes in technology since the study was undertaken are unlikely to yield different findings.

In summary, opportunities for enhanced diabetes service support were identified, with CSII in particular not currently appearing to achieve its full potential. Service structure needs to keep pace with the changes in technology and its rapid uptake by young people. Policy-makers and managers should align service delivery to patient goals and preferences to maximise service as well as patient benefit. This must include regular access to multidisciplinary team support with specialist medical input, which is particularly lacking for CSII users and those outside metropolitan areas.

ACKNOWLEDGEMENTS:

We acknowledge the support of the diabetes team from John Hunter Children's Hospital, particularly Helen Phelan, and from regional community health services, and their patients and families.

AUTHOR'S CONTRIBUTIONS:

Study proposal developed by LP, JL, JD and KS. Data collected by JD.

Analyses conducted by SJ and LP. Paper drafted, revised and agreed by all authors.

All authors read and approved the final manuscript.

Author Manuscript

REFERENCES

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med.* 1993;329:977-86.
2. Jeitler K, Horvath K, Berghold A, Gratzer T, Neeser K, Pieber T, Siebenhofer A. Continuous Subcutaneous Insulin Infusion versus multiple daily injections in patients with diabetes mellitus: systematic review and meta-analysis. *Diabetologia.* 2008;51(6):941-51.
3. Ludvigsson J, Samuelsson U. Continuous Insulin Infusion (CSII) or modern type of multiple daily injections (MDI) in diabetic children and adolescents: a critical review on a controversial issue. *Pediatric Endocrinology Review.* 2007;5(2):666-78.
4. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily injections in type 1 diabetes: a meta-analysis. *Acta Diabetologia.* 2010;47(Supp. 1):77-81.
5. Pickup J, Sutton A. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: a meta-analysis of multiple daily injections compared with continuous subcutaneous insulin infusion. *Diabet Med.* 2008;25(7):765-74.
6. Yeh H, Brown T, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analyses. *Ann Intern Med.* 2012;157(5):336-47.
7. Pankowska E, Blazik M, Dziechciarz P, Szypowska A, Szajewska H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. *Pediatr Diabetes.* 2009;10(1):52-8.
8. Steineck I, Cederholm J, Eliasson B, et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18168 people with type 1 diabetes: observational study. *BMJ.* 2015;350, DOI: 10.1136/bmj.h3234:1-9.
9. Misso M, Egberts K, Page M. Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. CD005103. *Cochrane Database Syst Rev.* 2010.
10. McMahon S, Airey F, Marangou D, McElwee K, Carne C, Clarey A, Davis E, Jones T. Insulin pump therapy in children and adolescents: improvements in key parameters of diabetes management including quality of life. *Diabet Med.* 2005;22:92-6.
11. Nicolucci A, Maione A, Franciosi M, et al. Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. *Diabet Med.* 2008;25(2):213-20.
12. Fatourehchi M, Kudva Y, Murad M, Elamin M, Tabini C, Montori V. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. *J Clin Endocrinol Metab.* 2009;94(3):729-40.
13. Wheeler B, Heels K, Donaghue K, Reith D, Ambler G. Insulin Pump - Associated Adverse Events in Children and Adolescents - A Prospective Study. *Diabetes Technol Ther.* 2014;16(9):1-5.
14. Lynch P, Riedel A, Samant N, Fan Y, Peoples T, Levinson J. Resource utilization with insulin pump therapy for type 2 diabetes mellitus. *Am J Manag Care.* 2010;16:892-6.

15. Cope J, Samuels-Reid J, Morrison A. Pediatric use of insulin pump therapy technology: a retrospective study of adverse events in children ages 1-12 years. *J Diabetes Sci Technol.* 2012;6(5):1053-9.
16. Australian Institute of Health and Welfare. Insulin pump use in Australia. Diabetes series no18; Cat no CVD 58 Australian Government: Canberra. 2012.
17. Selam J. CSII in Europe: where are we, where are we going? An analysis of articles published in Infosystems International. *Diabetes Res Clin Pract.* 2006;74((Suppl. 2)):s123-s6.
18. Alsaleh F, Smith F, Keady S, Taylor K. Insulin pumps: From inception to the present and toward the future. *J Clin Pharm Ther.* 2010;35:127-38.
19. Beck R, Tamborlane W, Bergenstal R, Miller K, DuBose S, Halk C. The T1D exchange clinic registry. *J Clin Endocrinol Metab.* 2012;97(12):4383-9.
20. Australian Institute of Health and Welfare. Incidence of type 1 diabetes in Australia 2000-2013, Available at: <http://apo.org.au/resource/incidence-type-1-diabetes-australia-2000-2013>, accessed 10th December 2015.
21. Department of Health. Diabetes, Available at: www.health.gov.au/internet/main/publishing.nsf/Content/chronic-diabetes, accessed 12th March 2016.
22. Diabetes Australia. National Diabetes Services Scheme - Product and Supply, Available at: <https://www.ndss.com.au/product-and-supply>, accessed 1st August 2016.
23. Hunter New England Health. Our District, Available at: www.hnehealth.nsw.gov.au/Pages/Our-District.aspx, accessed 10th March 2016.
24. Wallston K, Rothman R, Cherrington A. Psychometric Properties of the Perceived Diabetes Self-Management Scale (PDSMS). *Journal of Behavioural Medicine.* 2007;30:395-401.
25. Viklund G, Rudberg S, Wikblad K. Teenagers with diabetes: Self-management education and training on a big schooner. *International Journal of Nursing Practice.* 2007;13:385-92.
26. Australian Bureau of Statistics. Australian Standard Geographical Classification (ASC) Digital Boundaries, Australia, Available at <http://www.abs.gov.au/ausstats/abs@.nsf/mf/1259.0.30.001>, accessed 10th March 2016.
27. Donaghue K, Wadwa R, Dimeglio L, et al. Microvascular and macrovascular complications in children and adolescents. *Pediatr Diabetes.* 2014;15 (Suppl. 20):257-69.
28. Ajzen I, Fishbein M. Understanding attitudes and predicting social behaviour. Prentice Hall, New Jersey 1980.
29. Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, Lilos P, Dickerman Z, Phillip M. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. *Pediatrics.* 2003;112:559-64.
30. Hammond P, Liebl A, Grunder S. International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life. *Primary Care Diabetes.* 2007;1(3):143-6.
31. Perry L, Lowe J, Steinbeck K, Dunbabin J. Services doing the best they can: service experiences of young adults with type 1 diabetes mellitus in rural Australia. *J Clin Nurs.* 2012;21:1955-63.
32. American Diabetes Association. Standards of Medical Care in Diabetes - 2014. *Diabetes Care.* 2014;37:s14-s80.

33. Australian Type 1 Diabetes Guidelines Expert Advisory Group. National evidence-based clinical care guidelines for type 1 diabetes in children, adolescents and adults. Australian Government: Canberra. 2011.
34. James S, Gallagher R, Dunbabin J, Perry L. Prevalence of vascular complications and factors predictive of their development in young adults with type 1 diabetes: systematic literature review. *BMC Res Notes*. 2014;7(593):1-11.
35. James S, Perry L, Gallagher R, Lowe J, Dunbabin J, McElduff P, Acharya S, Steinbeck K. Service Usage and Vascular Complications in Young Adults with Type 1 Diabetes. *BMC Endocr Disorders*. 2014;14(39):1-9.
36. Perry L, Steinbeck K, Dunbabin J, Lowe J. Lost in transition? Access to and uptake of adult health services and outcomes for young people with type 1 diabetes in regional New South Wales. *Med J Aust*. 2010;193(8):444-9.
37. Craig M, Jones T, Silink M, Ping Y. Diabetes care, glycaemic control, and complications in children with type 1 diabetes from Asia and the Western Pacific Region. *Journal of Diabetes and Its Complications*. 2007;21(5):280-7.
38. Gerstl E, Rabl W, Rosenbauer J, Grobe H, Hofer S, Krause U, Holl R. Metabolic control as reflected by HbA1c in children, adolescents and young adults with type-1 diabetes mellitus: combined longitudinal analysis including 27,035 patients from 207 centres in Germany and Austria during the last decade. *European Journal of Pediatrics*. 2008;167:447-53.
39. Ozcan S, Amiel S, Rogers H, Choudhary P, Cox A, de Zoysa N, Hopkins D, Forbes A. Poorer glycaemic control in type 1 diabetes is associated with reduced self-management and poorer perceived health: A cross-sectional study. *Diabetes Res Clin Pract*. 2014;106(1):35-41.
40. The Australian National Adult Insulin Pump Therapy Working Group. Provision of Quality Care for Adults with Type 1 Diabetes Requiring Insulin Pump Therapy (IPT). *Infosyst Asia*. 2013;8(1):1-12.
41. de Bock M, Gunn A, Holt J-A, Derraik J, Reed P, Cutfield W, Mouat F, Hofman P, Jefferies C. Impact of insulin pumps on glycaemic control in a pump-naïve paediatric regional population. *J Paediatr Child Health*. 2012;48:247-52.
42. Hofer S, Heidtmann B, Raile K, Frohlich-Reiterer E, Lilienthal E, Berghaeuser M, Holl R. Discontinuation of insulin pump treatment in children, adolescents, and young adults. A multicenter analysis based on the DPV database in Germany and Austria. *Pediatr Diabetes*. 2010;11:116-21.
43. Acerini C. The rise of technology in diabetes care. Not all that is new is necessarily better. *Pediatr Diabetes*. 2016;17(3):168-73.
44. Perry L, James S, Gallagher R, Dunbabin J, Steinbeck K, Lowe J. Supporting patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: difficulties, disconnections and disarray. 2016. Paper in progress.
45. Dunbabin J, Perry L, Steinbeck K, Haas M, James S, Lowe J. Can Telehealth Engage Young People with Type 1 Diabetes? Experiences from the YOuR-Diabetes Project. *Aust Diabetes Educ*. 2015;18(3):32-4.

Table 1: Demographic details and reported glycaemic control

Variable	Overall [n107 unless stated]	Current CSII user [n42 unless stated]	Non-CSII user [n65 unless stated]	Test value	P value
Full-time student (n%)	98 (91.6)	39 (92.9)	59 (90.8)	-	-
Lives with family members (n%)	102 (95.3)	40 (95.2)	62 (95.4)	-	-
Male gender (n%)	62 (57.9)	24 (57.1)	38 (58.5)	$X^2 = .018$.893
Age, mean (SD, min-max) yrs	15.1 (2.0, 10.6 - 18.8)	15.4 (1.9, 12.3 - 18.4)	14.9 (2.1, 10.6 - 18.8)	$U = 1108.5$.102
Age at diagnosis, mean (SD, min-max) yrs	n104 9.3 (3.7, 0.9 - 16.8)	n41 8.4 (3.1, 1.5 - 14.5)	n63 9.8 (4, 0.9 - 16.8)	$U = 964$.029
Diabetes duration, mean (SD, min-max) yrs	n104 5.9 (3.5, 0.2 - 13.7)	n41 7.1 (2.7, 1.7 - 13.7)	n63 5.1 (3.7, 0.2 - 12.7)	$U = 796$.001
Metropolitan residence[†] (n%)	33 (30.8)	16 (38.1)	17 (26.2)	$X^2 = 1.706$.192
Most recent HbA1c (%), mean (SD, min - max)	n65 8.0 (1.6, 5.2 - 12.9)	n28 8.3 (1.4, 6.3 - 11.2)	n 37 7.8 (1.7, 5.2 - 12.9)	$t = 1.454$.151

[†] **Metropolitan versus non-metropolitan** according to Australian Standard Geographical Classification.

CSII = Continuous Subcutaneous Insulin Infusion. Yrs = Years. X^2 = Chi-square test. U = Mann-Whitney U -test. t = Student's t -test.

Table 2: Attitudes and perceptions (Perceived Diabetes Self-Management Scale-PDSMS)

	Overall	Current CSII user	Non-CSII user	Mann-Whitney U	P value
	Median (25, 75) score	Median (25, 75) score	Median (25, 75) score	test value	
Variable	[n86 unless stated]	[n36 unless stated]	[n50]		
Succeed in things to manage	4 (3, 4)	4 (3, 4)	4 (4, 5)	715	.076
Able to achieve plans	n85, 4 (3, 4)	n35, 4 (3, 4)	4 (4, 5)	747.5	.218
Manage as well as others	4 (4, 5)	4 (4, 5)	4 (4, 5)	813.5	.395
Handle diabetes well	4 (4, 5)	4 (4, 4.75)	4 (4, 5)	846	.607
Effective solutions†	4 (3, 4)	4 (3, 4)	4 (3,4)	869	.777
Doesn't turn out way liked†	4 (3, 5)	4 (3, 5)	4 (3, 4.25)	887	.906
Efforts to change don't work†	n85, 4 (3, 4)	n35, 4 (3,4)	4 (3,4)	863.5	.914
Plans don't work out well†	4 (3, 4)	4 (3, 4)	4 (3, 4)	899	.993
Summary score	n84, 31 (26, 34)	n34, 31 (26, 34)	31 (26.75, 36)	782.5	.537

†Reverse scored. 1 = Strongly disagree, 5 = Strongly agree. CSII = Continuous Subcutaneous Insulin Infusion.

Table 3: Multiple regression (backwards entry)

Independent	Dependent	Independence in care of diabetes†	PDSMS†	Disturbed by diabetes†	Independence changing insulin dosages†	Most recent HbA1c	Knowledge of diabetes†
		Beta (<i>P</i> value)	Beta (<i>P</i> value)	Beta (<i>P</i> value)	Beta (<i>P</i> value)	Beta (<i>P</i> value)	Beta (<i>P</i> value)
Sex				.193 (.060)			
Age overall		.490 (< .001)	-.324 (.003)			-.237 (.04)	-.341 (.019)
Metropolitan residence Yes/No				.213 (.037)	-.194 (.059)		
PDSMS†		.255 (.007)	-	-.688 (< .001)	.255 (.044)	-.632 (< .001)	
Knowledge of diabetes†		.227 (.015)		.266 (.015)			-
Independence changing		.288 (.004)			-	.345 (.005)	

insulin dosages†

Independence in care of .378 (.001) .535 (< .001) .572 (< .001)

diabetes†

Disturbed by diabetes† -.428 (< .001) -

Most recent HbA1c -.302 (.003) .356 (.004) -

Model number, R² 7, .626 7, .589 7, .495 7, .464 8, .382 9, .226

† = Summary score. n59. CSII = Continuous Subcutaneous Insulin Infusion. PDSMS = Perceived Diabetes Self-Management Scale.
The independent variables Current CSII use Yes/No and Diabetes duration overall were removed from all models.

Table 4: Service usage

Variable	Overall n (%) unless stated	Current CSII user n (%) unless stated	Non-CSII user n (%) unless stated	Test value	<i>P</i> value
Any DR ED presentation	n92	n34	n58	FET = not	.741
Yes	11 (12)	3 (8.8)	8 (13.8)	provided	
DR ED presentations, median (25, 75)	n11	n3	n8	<i>U</i> = 939	.50
	2 (1, 4)	2 (2,-)	1.5 (1, 4)		
Any DR hospital admission[†]	n96	n39	n57	$X^2 = < .001$.988
Yes	27 (28.1)	11 (28.2)	16 (28.1)		
DR hospital admissions[†], median (25, 75)	n27	n11	n16	<i>U</i> = 67.5	.318
	1 (1, 1)	1 (1, 1)	1 (1, 1)		
Any DR acute service usage[†]	n100	n40	n60	$X^2 = .008$.931
Yes	33 (33)	13 (32.5)	20 (33.3)		

DR acute service usage[†], median (25, 75)[‡]	n20	n5	n15	$U = 31.0$.612
	1 (1, 3.75)	1 (1, 2.5)	1 (1, 4)		

[†]Excluding admissions for type 1 diabetes diagnosis.

[‡]Data excluded from analysis where not present for both ED and hospital admissions.

CSII = Continuous Subcutaneous Insulin Infusion. DR = Diabetes-related.

ED = Emergency Department. X^2 = Chi-square test. FET = Fisher's Exact Test. U = Mann-Whitney U -test.